Latest News
Jul 2020 Pharmacokinetic bridge study of Rivamist™ nasal spray and Exelon® oral capsule successfully completed.
- Nasal delivers twice the rivastigmine exposure as oral at an equivalent 3 mg dose
- Rivastigmine and metabolite (NAP226-90) plasma concentration shown for nasal 4 mg (below left) and oral 3 mg (below right)
AusIndustry funding support acknowledged.
ACTRN12619001513101, Mean ± SD, n= 16
Scientific title: A randomised, crossover, two period, pharmacokinetic, bioavailability and safety study of a single dose of the novel rivastigmine nasal spray and single dose rivastigmine (Exelon, registered trademark) oral capsule in young healthy adult males.
Exelon is a registered trademark of Novartis Corp.
ACTRN12619001513101, Mean ± SD, n= 16
Scientific title: A randomised, crossover, two period, pharmacokinetic, bioavailability and safety study of a single dose of the novel rivastigmine nasal spray and single dose rivastigmine (Exelon, registered trademark) oral capsule in young healthy adult males.
Exelon is a registered trademark of Novartis Corp.
Jun 2020 Australian patent accepted for our nasal drug delivery technology.
Apr 2020 European patent intention to grant notice received for our nasal drug delivery technology.
Mar 2020 Rivamist trademark filed for our patented Rivastigmine nasal spray.
Dec 2020 Initial usability study of our Rivastigmine nasal spray device successfully completed in AD and PD dementia patients and their carers.
Sep 2019 AusIndustry AC grant received to support the development of our proprietary Rivastigmine nasal spray for AD and PD dementia.
Aug 2019 United States patent granted for our nasal drug delivery technology.
Apr 2020 European patent intention to grant notice received for our nasal drug delivery technology.
Mar 2020 Rivamist trademark filed for our patented Rivastigmine nasal spray.
Dec 2020 Initial usability study of our Rivastigmine nasal spray device successfully completed in AD and PD dementia patients and their carers.
Sep 2019 AusIndustry AC grant received to support the development of our proprietary Rivastigmine nasal spray for AD and PD dementia.
Aug 2019 United States patent granted for our nasal drug delivery technology.
Journal Publication
- Morgan TM, Soh B. Absolute Bioavailability and Safety of a Novel Rivastigmine Nasal Spray in Healthy Elderly Individuals. Br J Clin Pharmacol. 2017 83(3):510-516 PMID: 27639640 DOI: 10.1111/bcp.13133
Conference Posters
- Morgan TM. Deconvolution of Nasal Absorption of Rivastigmine in Humans and Future Clinical Development. J Prev Alz Dis 2016. 3(4):353; P2-39.
- Morgan TM. Absolute bioavailability and safety of a novel rivastigmine intranasal spray in healthy elderly individuals. J Prev Alz Dis 2015. 2(4):269-396; P2-55.